Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 67.6 CNY -0.5%
Market Cap: 50.1B CNY
Have any thoughts about
Hangzhou Tigermed Consulting Co Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

33.6
Current
34.3
Median
19.9
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
33.6
=
Enterprise Value
50.5B CNY
/
EBITDA
1.5B CNY
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
24.5
2-Years Forward
EV/EBITDA
20.3
3-Years Forward
EV/EBITDA
18.8

See Also

Discover More